The effects of a TRPV1 antagonist, SB- 705498, in the treatment of seasonal allergic rhinitis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 7, 2013, Pages 576-584

  Bareille, Philippe ^a   Murdoch, Robert D ^a   Denyer, Jane ^a   Bentley, Jane ^a   Smart, Kevin ^a   Yarnall, Katy ^a   Zieglmayer, Petra ^b   Zieglmayer, René ^b   Lemell, Patrick ^b   Horak, Friedrich ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Vienna Challenge Chamber   (Austria)

Author keywords

Intranasal SB 705498; Seasonal allergic rhinitis; TRPV1 antagonist

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; ALLERGEN; FLUTICASONE PROPIONATE; PLACEBO; VANILLOID RECEPTOR 1;

ADULT; ALLERGY TEST; ARTICLE; AUSTRIA; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HAY FEVER; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NASAL DISCOMFORT; NOSE AIRFLOW; NOSE DISEASE; OUTCOME ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SNEEZING; SYMPTOM; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL NASAL SYMPTOM SCORE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRANASAL; ADULT; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; AUSTRIA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PYRROLIDINES; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; TRPV CATION CHANNELS; UREA;

EID: 84880223161     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201890     Document Type: Article

References (35)

1. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schünemann HJGlobal Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126: 466-476. CrossRef PubMed
2. Laforest L, Bousquet J, Pietri G, Sazonov Kocevar V, Yin D, Pacheco Y, Van Ganse E. Quality of life during pollen season in patients with seasonal allergic rhinitis with or without asthma. Int Arch Allergy Immunol. 2005; 136: 281-286. CrossRef PubMed (Pubitemid 40529200)
3. Kauppi P, Salo P, Hakola R, Pentti J, Oksanen T, Kivimäki M, Vahtera J, Haahtela T. Allergic rhinitis alone or with asthma is associated with an increased risk of sickness absences. Respir Med. 2010; 104: 1654-1658. CrossRef PubMed
4. Blaiss MS; Allergic Rhinitis in Schoolchildren Consensus Group. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin. 2004; 20: 1937-1952. Cross- Ref PubMed (Pubitemid 40179633)
5. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc. 2010; 31: 375-380. CrossRef PubMed
6. Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the common coldhigh cost to society. Allergy. 2010; 65: 776-783. CrossRef PubMed
7. Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, Ryan D, Walker SM, Clark AT, Dixon TA, Jolles SRA, Siddique N, Cullinan P, Howarth PH, Nasser SM; British Society for Allergy and Clinical Immunology. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008; 38: 19-42. CrossRef PubMed (Pubitemid 350233401)
8. Price D, Bond C, Bouchard J, Costa R, Keenan J, Levy ML, Orru M, Ryan D, Walker S, Watson M. International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. Prim Care Respir J. 2006; 15: 58-70. Cross- Ref PubMed (Pubitemid 43155767)
9. Badorrek P, Dick M, Schauerte A, Hecker H, Murdoch R, Luettig B, Hohlfeld JM, Krug N. A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis. Int J Clin Pharmacol Ther. 2009; 47: 71-77. PubMed
10. Zieglmayer P, Zieglmayer R, Bareille P, Rousell V, Salmon E, Horak F. Fluticasone furoate vs. placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin. 2008; 24: 1833-1840. CrossRef PubMed (Pubitemid 351929081)
11. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011; 378: 2112-2122. CrossRef PubMed
12. Sarin S, Undem B, Sanico A, Togias A. The role of the nervous system in rhinitis. J Allergy Clin Immunol. 2006; 118: 999-1016. CrossRef PubMed
13. Van Gerven L, Boeckxstaens G, Hellings PW. Update on neuro-immune mechanisms involved in allergic and non-allergic rhinitis. Rhinology. 2012; 50: 227-235. PubMed
14. Togias A. H1-receptors: localization and role in airway physiology and in immune functions. J Allergy Clin Immunol. 2003; 112 (Suppl): S60-S68. CrossRef PubMed (Pubitemid 37243978)
15. Alenmyr L, Herrmann A, Högestätt ED, Greiff L, Zygmunt PM. TRPV1 and TRPA1 stimulation induces MUC5B secretion in the human nasal airway in vivo. Clin Physiol Funct Imaging. 2011; 31: 435-444. CrossRef PubMed
16. Geppetti P, Materazzi S, Nicoletti P. The transient receptor potential vanilloid 1: role in airway inflammation and disease. Eur J Pharmacol. 2006; 533: 207-214. CrossRef PubMed (Pubitemid 43348347)
17. Greiff L, Svensson C, Andersson M, Persson CGA. Effects of topical capsaicin in seasonal allergic rhinitis. Thorax. 1995; 50: 225-229. Cross- Ref PubMed
18. Alenmyr L, Högestätt ED, Zygmunt PM, Greiff L. TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009; 64: 807-810. CrossRef PubMed
19. Delescluse I, Mace H, Adcock JJ. Inhibition of airway hyper-responsiveness by TRPV1 antagonists (SB-705498 and PF-04065463) in the unanaesthetized, ovalbumin-sensitized guinea pig. Br J Pharmacol. 2012; 166: 1822-1832. CrossRef PubMed
20. Holland C, Segboer C, Tsitoura D, Newlands A, Bareille P, Denyer J, van Drunen K, Fokkens W. Pharmacological assessment of the effects of SB- 705498 on capsaicin-induced responses in healthy volunteers and patients with non-allergic rhinitis. European Respiratory Society - 21st Annual Congress. 2011.
21. Day JH, Horak F, Briscoe MP, Canonica GW, Fineman SM, Krug N, Leynadier F, Lieberman P, Quirce S, Takenaka H, Cauwenberge P. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev. 2006; 6: 31-59. CrossRef
22. Horak F, Stübner UP, Zieglmayer R, Harris AG. Effect of desloratadine vs. placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol. 2002; 109: 956-961. CrossRef PubMed (Pubitemid 34634305)
23. Horak F, Stübner P, Zieglmeyer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy. 2003; 58: 481-485. Cross- Ref PubMed (Pubitemid 36649307)
24. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999; 104: 364-369. CrossRef PubMed (Pubitemid 29420434)
25. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996; 98: 843-845. CrossRef PubMed (Pubitemid 26357253)
26. Vervloet D, Charpin D, Desfourgeres J-L. Intranasal fluticasone once daily compared with once-daily cetirizine in the treatment of seasonal allergic rhinitis. Clin Drug Investig. 1997; 13: 291-298. CrossRef (Pubitemid 27279630)
27. Ortolani C, Foresi A, Di Lorenzo G et al. A doubleblind comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal rhinitis. Allergy. 1999; 54: 1175-1180. CrossRef PubMed
28. Bronsky EA, Dockhorn RJ, Meltzer EO, Shapiro G, Boltansky H, LaForce C, Ransom J, Weiler JM, Blumenthal M, Weakley S, Wisniewski M, Field E, Rogenes P. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 1996; 97: 915-921. CrossRef PubMed (Pubitemid 26116984)
29. Jen A, Baroody F, de Tineo M, Haney L, Blair C, Naclerio R. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2000; 105: 732-738. CrossRef PubMed (Pubitemid 30226447)
30. Hohlfeld JM, Holland-Letz T, Larbig M, Lavae- Mokhtari M, Wierenga E, Kapsenberg M, van Ree R, Krug N, Bufe A. Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions. Clin Exp Allergy. 2010; 40: 998-1006. CrossRef PubMed
31. Knipping S, Holzhausen HJ, Riederer A, Schrom T. Allergic and idiopathic rhinitis: an ultrastructural study. Eur Arch Otorhinolaryngol. 2009; 266: 1249-1256. CrossRef PubMed
32. Raap U, Braunstahl G-J. The role of neurotrophins in the pathophysiology of allergic rhinitis. Curr Opin Allergy Clin Immunol. 2010; 10: 8-13. CrossRef PubMed
33. O'Hanlon S, Facer P, Simpson KD, Sandhu G, Saleh HA, Anand P. Neuronal markers in allergic rhinitis: expression and correlation with sensory testing. Laryngoscope. 2007; 117: 1519-1527. CrossRef PubMed (Pubitemid 47357378)
34. Alenmyr L, Greiff L, Andersson M, Sterner O, Zygmunt PM, Högestätt ED. Effect of mucosal TRPV1 inhibition in allergic rhinitis. Basic Clin Pharmacol Toxicol. 2012; 110: 264-268. Cross- Ref PubMed
35. Murdoch R, Bareille P, Bentley J, Newlands A, Smart K, Patel D. TRPV1 is not a target for the treatment of non-allergic rhinitis: a clinical study. Thorax. 2012; 67 (Suppl 2): A129. CrossRef